skip to primary navigationskip to content
 

SORCE kidney cancer trial results published

last modified Dec 07, 2020 05:55 PM

Tim EisenTrial results, published in the Journal of Clinical Oncology by Professor Tim Eisen (Department of Oncology and CRUK Cambridge Centre Urological Malignancies Programme), have concluded that active observation remains the best care for kidney cancer patients after surgery. Over 1,700 patients participated in the double-blind, randomised trial assessing the efficacy of sorafenib (a tyrosine kinase inhibitor also known as Nexavar) for prolonging life and preventing recurrence of kidney cancer in patients who are at medium or high risk of their cancer returning.
More information